Browse > Article
http://dx.doi.org/10.4142/jvs.22069

Long-term treatment of allogeneic adipose-derived stem cells in a dog with rheumatoid arthritis  

Seo, Min-Gyeong (Department of Veterinary Pathology, College of Veterinary Medicine, Gyeongsang National University)
Park, Seil (Cardiovascular Product Evaluation Center, College of Medicine, Yonsei University)
Han, Seonyoung (Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University)
Kim, Ah-Young (Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University)
Lee, Eun-Joo (Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University)
Jeong, Kyu-Shik (Department of Veterinary Pathology, College of Veterinary Medicine, Kyungpook National University)
Hong, Il-Hwa (Department of Veterinary Pathology, College of Veterinary Medicine, Gyeongsang National University)
Publication Information
Journal of Veterinary Science / v.23, no.4, 2022 , pp. 61.1-61.10 More about this Journal
Abstract
Background: Although there are growing demands for stem cell-based therapy for companion animals in various diseases, a few clinical trials have been reported. Moreover, most of them are the results from only one or a few times of stem cell injection. Objectives: The aim of this study is to describe a long-term treatment with allogeneic adipose-derived stem cells (ASCs) in a dog with rheumatoid arthritis (RA), which is a rare canine disease. Methods: The dog with RA received intravascular injection of allogeneic ASCs derived from two healthy donors once a month for 11 months. To assess therapeutic effects of ASCs, orthopedic examination and clinical evaluation was performed. Cytokines of tumor necrosis factor-α and interleukin-6 in the plasma were measured using ELISA analysis. Results: Despite this repeated and long-term administration of allogeneic ASCs, there were no side effects such as immunorejection responses or cell toxicity. The orthopedic examination score for the dog decreased after ASCs treatment, and the clinical condition of the dog and owner's satisfaction were very good Conclusions: Although ASCs has been suggested as one of the options for RA treatment because of its anti-inflammatory and immunosuppressive functions, it has never been used to treat RA in dogs. The present report describes a case of canine RA treated with allogeneic ASCs for long-term in which the dog showed clinical improvement without adverse effects.
Keywords
Dog; immune-mediated disease; immunomodulation; mesenchymal stem cell; rheumatoid arthritis;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Stone M. Immune-mediated polyarthritis and other polyarthritides. In: Ettinger SJ, Feldman EC, editors. Textbook of Veterinary Internal Medicine: Diseases of the Dog and Cat, Vol 1. 8th ed. Saint Louis: WB Saunders; 2017, 2151-2160.
2 Brunner CJ. Automimmunity. In: Bonagura JD, editor. Kirk's Current Veterinary Therapy Small Animal Practice. 12th ed. Philadelphia: WB Saunders; 1995, 559-560.
3 Ansboro S, Roelofs AJ, De Bari C. Mesenchymal stem cells for the management of rheumatoid arthritis: immune modulation, repair or both? Curr Opin Rheumatol. 2017;29(2):201-207.   DOI
4 Hegemann N, Wondimu A, Kohn B, Brunnberg L, Schmidt MF. Cytokine profile in canine immunemediated polyarthritis and osteoarthritis. Vet Comp Orthop Traumatol. 2005;18(2):67-72.   DOI
5 Frese L, Dijkman PE, Hoerstrup SP. Adipose tissue-derived stem cells in regenerative medicine. Transfus Med Hemother. 2016;43(4):268-274.   DOI
6 Liang J, Li X, Zhang H, Wang D, Feng X, Wang H, et al. Allogeneic mesenchymal stem cells transplantation in patients with refractory RA. Clin Rheumatol. 2012;31(1):157-161.   DOI
7 Wright HL, Moots RJ, Edwards SW. The multifactorial role of neutrophils in rheumatoid arthritis. Nat Rev Rheumatol. 2014;10(10):593-601.   DOI
8 Craig LE, Dittmer KE, Thompson KG. Bones and joints. In: Maxie MG, editors. Jubb, Kennedy and Palmer's Pathology of Domestic Animals, Vol 1. 6th ed. Saint Louis: WB Saunders; 2016, 157-159.
9 Heuser W. Canine rheumatoid arthritis. Can Vet J. 1980;21(11):314-316
10 Wang L, Huang S, Li S, Li M, Shi J, Bai W, et al. Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I/II study. Drug Des Devel Ther. 2019;13:4331-4340.   DOI
11 Lopez-Santalla M, Fernandez-Perez R, Garin MI. Mesenchymal stem/stromal cells for rheumatoid arthritis treatment: an update on clinical applications. Cells. 2020;9(8):1852.   DOI
12 Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford). 2012;51 Suppl 6:vi37-vi43.
13 Ueyama H, Okano T, Orita K, Mamoto K, Ii M, Sobajima S, et al. Local transplantation of adiposederived stem cells has a significant therapeutic effect in a mouse model of rheumatoid arthritis. Sci Rep. 2020;10(1):3076.   DOI
14 Gingerich DA, Strobel JD. Use of client-specific outcome measures to assess treatment effects in geriatric, arthritic dogs: controlled clinical evaluation of a nutraceutical. Vet Ther. 2003;4(1):56-66.
15 Wasserman AM. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2011;84(11):1245-1252.
16 McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.   DOI
17 Karamini A, Bakopoulou A, Andreadis D, Gkiouras K, Kritis A. Therapeutic potential of mesenchymal stromal stem cells in rheumatoid arthritis: a systematic review of in vivo studies. Stem Cell Rev Rep. 2020;16(2):276-287.   DOI
18 Dias IE, Pinto PO, Barros LC, Viegas CA, Dias IR, Carvalho PP. Mesenchymal stem cells therapy in companion animals: useful for immune-mediated diseases? BMC Vet Res. 2019;15(1):358.   DOI
19 Black LL, Gaynor J, Gahring D, Adams C, Aron D, Harman S, et al. Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial. Vet Ther. 2007;8(4):272-284.
20 Johnson KC, Mackin A. Canine immune-mediated polyarthritis: part 2: diagnosis and treatment. J Am Anim Hosp Assoc. 2012;48(2):71-82.   DOI
21 Kang MH, Park HM. Challenges of stem cell therapies in companion animal practice. J Vet Sci. 2020;21(3):e42.   DOI
22 Chevrel G, Jenvrin C, McGregor B, Miossec P. Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatology (Oxford). 2001;40(7):821-825.   DOI
23 Alvaro-Gracia JM, Jover JA, Garcia-Vicuna R, Carreno L, Alonso A, Marsal S, et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann Rheum Dis. 2017;76(1):196-202.   DOI
24 Gugjoo MB, Amarpal A, Sharma GT. Mesenchymal stem cell basic research and applications in dog medicine. J Cell Physiol. 2019;234(10):16779-16811.   DOI
25 Olson EJ, Carlson CS. Bones, joints, tendons, and ligaments. In: Zachary JF, editor. Pathologic Basis of Veterinary Disease. 6th ed. Saint Louis: Mosby; 2017, 1008.
26 Kabat M, Bobkov I, Kumar S, Grumet M. Trends in mesenchymal stem cell clinical trials 2004-2018: is efficacy optimal in a narrow dose range? Stem Cells Transl Med. 2020;9(1):17-27.   DOI